Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The company develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and make treatments more effective at destroying cancer cells while sparing healthy tissue. Its approach centers on synthetic lethality, a biological phenomenon where inhibiting specific genes in cancer cells with defined mutations leads to selective cell death while minimizing effects on normal cells. Aprea Therapeutics, Inc. was originally incorporated in 2002 and commenced principal operations in 2006 through its subsidiary Aprea Therapeutics AB, which became a wholly-owned subsidiary after a reorganization on September 20, 2019. The company enhanced its pipeline following the acquisition of Atrin Pharmaceuticals Inc. in May 2022 and now focuses on developing synthetic lethality-based cancer therapeutics.
Aprea Therapeutics, Inc. generates revenue through the development and potential commercialization of its product candidates, which are small molecule inhibitors targeting key proteins in the DNA damage response pathway. The company does not currently have any marketed products or commercial revenue, as all its programs are in preclinical or clinical development stages. Revenue generation is expected to occur in the future through sales of approved therapies, potential licensing agreements, or strategic partnerships once its product candidates receive regulatory approval. The company retains worldwide development and commercialization rights to all its product candidates and may evaluate strategic partnerships to complement its capabilities.
The company operates through the following segments:
- APR-1051: This segment involves the development of a WEE1 inhibitor product candidate designed to target tumors with mutations in PPP2R1A, FBXW7, or increased expression of Cyclin E1. APR-1051 is an orally bioavailable small molecule inhibitor currently in Phase 1 clinical trials (ACESOT-1051) for patients with advanced solid tumors. The study evaluates safety, dose-limiting toxicities, maximum tolerated dose, and recommended Phase 2 dose, with preliminary evidence of anti-tumor activity observed in patients with PPP2R1A-mutated endometrial cancer.
- ATRN-119: This segment involves the development of an ATR inhibitor product candidate, also known as Mosipasertib, which is the first oral macrocyclic ATR inhibitor to enter clinical trials. ATRN-119 is being evaluated in a Phase 1/2a dose-escalation study (ABOYA-119) for patients with advanced solid tumors having mutations in defined DNA damage response-related genes. The recommended Phase 2 dose was determined to be 1,100 mg once daily, and the company is exploring combination approaches with radiation therapy, antibody-drug conjugates, and immune checkpoint inhibitors to expand therapeutic potential.
- APR-1602: This segment involves an early-stage preclinical program for a macrocyclic DYRK1A/B inhibitor. APR-1602 is expected to be ready to enter IND-enabling studies in the fourth quarter of 2026 and represents a potential future addition to the company's pipeline of synthetic lethality-based therapeutics.
Aprea Therapeutics, Inc. operates in the highly competitive oncology therapeutics industry, where it faces competition from large pharmaceutical companies, specialty pharmaceutical firms, and biotechnology enterprises developing similar targeted therapies. Key competitors for its WEE1 inhibitor APR-1051 include Zentalis Pharmaceuticals, Debiopharm, IMPACT Therapeutics, Schrodinger, and Acrivon Therapeutics, some of whom have discontinued or are evaluating WEE1 inhibitors in clinical trials. For its ATR inhibitor ATRN-119, competitors include Artios Pharma, AstraZeneca, IMPACT Therapeutics, Merck KGaA, and Xeno Therapeutics (formerly Repare Therapeutics’ ATR inhibitor program). The company's competitive advantages lie in the selectivity and potency of its product candidates, such as APR-1051’s high selectivity for WEE1 over off-target kinases like PLK1, PLK2, and PLK3, and ATRN-119’s macrocyclic structure designed to increase selectivity for ATR over related PIKK family kinases including ATM, DNA-PK, and mTOR, which may reduce toxicity and permit higher efficacious dosing.
Aprea Therapeutics, Inc. serves patients with biomarker-defined cancers who have high unmet medical needs, particularly those with solid tumors harboring specific genetic mutations in DNA damage response genes such as PPP2R1A, FBXW7, CCNE1 overexpression, or other DDR-related alterations. The company's clinical trials enroll patients with advanced solid tumors, including uterine serous carcinoma, endometrial cancer, head and neck squamous cell carcinoma, colon cancer, and ovarian cancer, among others. The customer base consists of individuals receiving treatment through healthcare providers such as oncologists and cancer treatment centers, with no specific customer names disclosed in the filing.